Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan

INTRODUCTION: The median survival time of patients with advanced soft tissue sarcoma (STS) is typically <12 months. Since 2012, physicians were able to administer second- and/or third-line treatment easily in Japan, following the approval of new drugs, namely, pazopanib, eribulin, and trabectedin...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Tomoki, Asanuma, Kunihiro, Hagi, Tomohito, Sudo, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567542/
https://www.ncbi.nlm.nih.gov/pubmed/33116409
http://dx.doi.org/10.2147/DDDT.S275526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567542/
https://www.ncbi.nlm.nih.gov/pubmed/33116409
http://dx.doi.org/10.2147/DDDT.S275526

Ejemplares similares